{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.1","upperLimit":"81.4","value":"66.7"},{"groupId":"OG001","lowerLimit":"32.5","upperLimit":"79.4","value":"57.1"},{"groupId":"OG002","lowerLimit":"2.6","upperLimit":"97.5","value":"50.0"},{"groupId":"OG003","lowerLimit":"22.4","upperLimit":"100","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"description":"9-month OS rate is the percentage of participants alive at 9 months from registration.","dispersionType":"90% Confidence Interval","groups":[{"description":"Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).\n\nRadiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy\n\nBevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles","id":"OG000","title":"Cohort 1: MGMT-/EGFR-"},{"description":"Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).\n\nRadiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy\n\nBevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles\n\nErlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles","id":"OG001","title":"Cohort 2: MGMT-/EGFR+"},{"description":"Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).\n\nRadiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy\n\nBevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles\n\nTemozolomide: Administered orally at 90 mg/m2/day continuously during radiation therapy, held through the interim period and then 200 mg/m2/day for 5 days for up to 10 maintenance cycles","id":"OG002","title":"Cohort 3. MGMT+/EGFR-"},{"description":"Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).\n\nRadiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy\n\nBevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles\n\nErlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles","id":"OG003","title":"Cohort 4. MGMT+/EGFR+"}],"paramType":"NUMBER","populationDescription":"The analysis population is comprised of the subset of participants who underwent surgical biopsy, obtained a molecularly-based treatment assignment and started assigned chemoradiation therapy.","reportingStatus":"POSTED","timeFrame":"9 months","title":"9-month Overall Survival (OS) Rate by Molecular Cohort","type":"POST_HOC","unitOfMeasure":"percentage of participants"}